The course of metastatic prostate cancer under treatment
Yazarlar (5)
Aslan Demir
Kafkas Üniversitesi, Türkiye
Kursat Cecen
Kafkas Üniversitesi, Türkiye
Mert Ali Karadag
Kafkas Üniversitesi, Türkiye
Prof. Dr. Ramazan KOCAASLAN Kafkas Üniversitesi, Türkiye
Levent Turkeri
Marmara Üniversitesi, Türkiye
Makale Türü Açık Erişim Özgün Makale (SSCI, AHCI, SCI, SCI-Exp dergilerinde yayınlanan tam makale)
Dergi Adı Springerplus
Dergi ISSN 2193-1801 Wos Dergi Scopus Dergi
Dergi Tarandığı Indeksler SCI-Expanded
Makale Dili İngilizce Basım Tarihi 12-2014
Kabul Tarihi 06-11-2014 Yayınlanma Tarihi 01-12-2014
Cilt / Sayı / Sayfa 3 / 1 / 1–5 DOI 10.1186/2193-1801-3-725
Makale Linki http://www.springerplus.com/content/3/1/725
UAK Araştırma Alanları
Üroloji
Özet
The first-line management of metastatic prostate cancer is hormonal therapy. However, resistance to this treatment will emerge within an average of 24 months. Our purpose was to determine the course of metastatic prostate cancer under treatment.A total of 56 patients who were diagnosed with metastatic prostate cancer were enrolled. As initial management, 3 kinds of hormonal therapy consisting of bilateral orchiectomy (BSO) alone, BSO + anti-androgene (AA) and LH-RH + AA were applied. The patients were followed until the emergence of hormone resistance. Serum PSA levels at the time of first diagnosis, post-treatment nadir PSA levels, time to nadir PSA, time to hormonal resistance and PSA levels at hormonal resistance were assessed, retrospectively. The localization and number of metastases and the survival term from the beginning of the emergence of hormone resistance until death were investigated …
Anahtar Kelimeler
Course | Metastatic prostate cancer | Treatment modality
BM Sürdürülebilir Kalkınma Amaçları
Atıf Sayıları
Web of Science 4
Scopus 6
Google Scholar 9
The course of metastatic prostate cancer under treatment

Paylaş